VAC053B: Follow-up immunology bleed
Research type
Research Study
Full title
A follow-up study to assess the long-term immunogenicity of a protein particle malaria vaccine candidate, R21, administered with Matrix-M1 in healthy UK volunteers
IRAS ID
239945
Contact name
Adrian V.S Hill
Contact email
Sponsor organisation
University of Oxford, CTRG
Duration of Study in the UK
0 years, 4 months, 0 days
Research summary
A follow-up study to assess the immune response to the candidate malaria vaccine R21 administered with matrix-M (tested in the VAC053 clinical trial).
Plasmodium falciparum Malaria remains a major global health problem with approximately 200 million cases and 430,000 deaths worldwide annually, mostly in Africa. The majority of these deaths are in children under the age of 5 years old. Current malarial control strategies confront numerous complex challenges including emergence of parasite resistance to drug treatment and the development of resistance of the mosquito vector to certain insecticides. A deployable malaria vaccine is therefore a key strategy for reducing malaria mortality and achieving the greater goal of global eradication of the disease. Clinical trials of vaccine candidates have only delivered partial efficacy someway short of the target 75% protective efficacy outlined for a deployable malaria vaccine by 2030.
The vaccine tested in this study, R21 / Matrix M has entered trials in Oxford that assess how effective it can be at protecting against malaria infection. These are termed malaria challenge studies in which volunteers, following vaccination, are infected with malaria by mosquito bite under controlled clinical conditions. The results from this study appear encouraging. In this study, participants who have already received R21/Matrix-M some time ago will have follow-up blood test to evaluate the immune response.REC name
North West - Liverpool Central Research Ethics Committee
REC reference
18/NW/0150
Date of REC Opinion
7 Mar 2018
REC opinion
Favourable Opinion